Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
crispr-cas9
3
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
editas medicine
eli lilly
fda
gene editing
glaxosmithkline
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
a2 biotherapeutics
aduro biotech
advaxis
agency
agios therapeutics
aimmune therapeutics
akili interactive labs
What
crispr
3
×
bio
cas
editas
medicine
roundup
scientists
alliance
beam
big
bosley's
bosley’s
bridge
bristol
bucks
buy
calls
ceo
changing
color
crime
days
departure
editing
editor
exit
founders
gene
gotten
growing
guiding
harvard
hours
jump
katrine
kudos
leaves
mass
moves
myers’s
Language
unset
Current search:
crispr
×
crispr-cas9
×
biotech
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M